Esomeprazol w terapii GERD: szybka ulga i trwałe efekty. Przegląd aktualnych dowodów klinicznych Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
lip 27, 2026
Słowa kluczowe:
esomeprazol, refluks żołądkowo-przełykowy, zgaga
##plugins.themes.bootstrap3.article.main##
Abstrakt
Esomeprazol jest inhibitorem pompy protonowej stosowanym w chorobie refluksowej przełyku. W porównaniu z innymi lekami z tej grupy charakteryzuje się korzystnym profilem farmakokinetycznym, większą i bardziej przewidywalną ekspozycją ogólnoustrojową oraz większą biodostępnością po dawkowaniu wielokrotnym. Esomeprazol skuteczne łagodzi objawy choroby, przyczynia się do gojenia nadżerek w przebiegu nadżerkowego zapalenia przełyku oraz pozwala na utrzymanie remisji po wygojeniu zmian. Żeby uzyskać optymalny efekt terapeutyczny, terapia tym lekiem musi być zindywidualizowana, musi on być prawidłowo przyjmowany przed posiłkiem oraz należy wykonywać okresowe oceny potrzeby kontynuacji leczenia i dążyć do podawania najmniejszej skutecznej dawki.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Caban, M., & Małecka-Wojciesko, E. (2026). Esomeprazol w terapii GERD: szybka ulga i trwałe efekty. Przegląd aktualnych dowodów klinicznych. Medycyna Faktów . Pobrano z https://www.journalsmededu.pl/index.php/jebm/article/view/3527
Numer
Dział
Artykuły
Copyright by Medical Education. All rights reserved.
Bibliografia
1. Katz PO, Dunbar KB, Schnoll-Sussman FH et al. ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease. Am J Gastroenterol. 2022; 117(1): 27-56. http://doi.org/10.14309/ajg.0000000000001538.
2. Yadlapati R, Gyawali CP, Pandolfino JE et al. AGA Clinical Practice Update on the Personalized Approach to the Evaluation and Management of GERD: Expert Review. Clin Gastroenterol Hepatol. 2022; 20(5): 984-994.e1. http://doi.org/10.1016/j.cgh.2022.01.025.
3. Scott LJ, Dunn CJ, Mallarkey G et al. Esomeprazole: a review of its use in the management of acid-related disorders. Drugs. 2002; 62(10): 1503-38. http://doi.org/10.2165/00003495-200262100-00006.
4. Andersson T, Hassan-Alin M, Hasselgren G et al. Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole. Clin Pharmacokinet. 2001; 40(6): 411-26. http://doi.org/10.2165/00003088-200140060-00003.
5. Andersson T, Röhss K, Hassan-Alin M et al. Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole. Aliment Pharmacol Ther. 2001; 15(10): 1563-9. http://doi.org/10.1046/j.1365-2036.2001.01087.x.
6. Sostek MB, Chen Y, Andersson T. Effect of timing of dosing in relation to food intake on the pharmacokinetics of esomeprazole. Br J Clin Pharmacol. 2007; 64(3): 386-90. http://doi.org/10.1111/j.1365-2125.2007.02889.x.
7. Miner P Jr, Katz PO, Chen Y et al. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol. 2003; 98(12): 2616-20. http://doi.org/10.1111/j.1572-0241.2003.08783.x.
8. Targownik LE, Fisher DA, Saini SD. AGA Clinical Practice Update on De-Prescribing of Proton Pump Inhibitors: Expert Review. Gastroenterology. 2022; 162(4): 1334-42. http://doi.org/10.1053/j.gastro.2021.12.247.
9. Richter JE, Kahrilas PJ, Johanson J et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol. 2001; 96(3): 656-65.
10. Castell DO, Kahrilas PJ, Richter JE et al. Esomeprazole 40 mg compared with lansoprazole 30 mg in the treatment of erosive esophagitis. Am J Gastroenterol. 2002; 97(3): 575-83.
11. Fennerty MB, Johanson JF, Hwang C et al. Efficacy of esomeprazole 40 mg vs. lansoprazole 30 mg for healing moderate to severe erosive oesophagitis. Aliment Pharmacol Ther. 2005; 21(4): 455-63. http://doi.org/10.1111/j.1365-2036.2005.02339.x.
12. Labenz J, Armstrong D, Lauritsen K et al. A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: the EXPO study. Aliment Pharmacol Ther. 2005; 21(6): 739-46. http://doi.org/10.1111/j.1365-2036.2005.02368.x.
13. Gralnek IM, Dulai GS, Fennerty MB et al. Esomeprazole versus other proton pump inhibitors in erosive esophagitis: a meta-analysis of randomized clinical trials. Clin Gastroenterol Hepatol. 2006; 4(12): 1452-8. http://doi.org/10.1016/j.cgh.2006.09.013.
14. Yang S, Deng W, Xie Z et al. Efficacy and safety of proton pump inhibitors versus vonoprazan in treatment of erosive esophagitis: A PRISMA-compliant systematic review and network meta-analysis. Medicine (Baltimore). 2022; 101(47): e31807. http://doi.org/10.1097/MD.0000000000031807.
15. DeVault KR, Johanson JF, Johnson DA et al. Maintenance of healed erosive esophagitis: a randomized six-month comparison of esomeprazole twenty milligrams with lansoprazole fifteen milligrams. Clin Gastroenterol Hepatol. 2006; 4(7): 852-9.
16. Katz PO, Castell DO, Levine D. Esomeprazole resolves chronic heartburn in patients without erosive oesophagitis. Aliment Pharmacol Ther. 2003; 18: 875-82. http://doi.org/10.1046/j.1365-2036.2003.01771.x.
17. Armstrong D, Talley NJ, Lauritsen K et al. The role of acid suppression in patients with endoscopy-negative reflux disease: the effect of treatment with esomeprazole or omeprazole. Aliment Pharmacol Ther. 2004; 20(4): 413-21. http://doi.org/10.1111/j.1365-2036.2004.02085.x.
18. Mönnikes H, Pfaffenberger B, Gatz G et al. Novel measurement of rapid treatment success with ReQuest: first and sustained symptom relief as outcome parameters in patients with endoscopy-negative GERD receiving 20 mg pantoprazole or 20 mg esomeprazole. Digestion. 2005; 71(3): 152-8. http://doi.org/10.1159/000086784.
19. Johnson DA, Le Moigne A, Hugo V et al. Rapid resolution of sleep disturbances related to frequent reflux: effect of esomeprazole 20 mg in two randomized, double-blind, controlled trials. Curr Med Res Opin. 2015; 31(2): 243-50. http://doi.org/10.1185/03007995.2014.991818.
2. Yadlapati R, Gyawali CP, Pandolfino JE et al. AGA Clinical Practice Update on the Personalized Approach to the Evaluation and Management of GERD: Expert Review. Clin Gastroenterol Hepatol. 2022; 20(5): 984-994.e1. http://doi.org/10.1016/j.cgh.2022.01.025.
3. Scott LJ, Dunn CJ, Mallarkey G et al. Esomeprazole: a review of its use in the management of acid-related disorders. Drugs. 2002; 62(10): 1503-38. http://doi.org/10.2165/00003495-200262100-00006.
4. Andersson T, Hassan-Alin M, Hasselgren G et al. Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole. Clin Pharmacokinet. 2001; 40(6): 411-26. http://doi.org/10.2165/00003088-200140060-00003.
5. Andersson T, Röhss K, Hassan-Alin M et al. Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole. Aliment Pharmacol Ther. 2001; 15(10): 1563-9. http://doi.org/10.1046/j.1365-2036.2001.01087.x.
6. Sostek MB, Chen Y, Andersson T. Effect of timing of dosing in relation to food intake on the pharmacokinetics of esomeprazole. Br J Clin Pharmacol. 2007; 64(3): 386-90. http://doi.org/10.1111/j.1365-2125.2007.02889.x.
7. Miner P Jr, Katz PO, Chen Y et al. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol. 2003; 98(12): 2616-20. http://doi.org/10.1111/j.1572-0241.2003.08783.x.
8. Targownik LE, Fisher DA, Saini SD. AGA Clinical Practice Update on De-Prescribing of Proton Pump Inhibitors: Expert Review. Gastroenterology. 2022; 162(4): 1334-42. http://doi.org/10.1053/j.gastro.2021.12.247.
9. Richter JE, Kahrilas PJ, Johanson J et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol. 2001; 96(3): 656-65.
10. Castell DO, Kahrilas PJ, Richter JE et al. Esomeprazole 40 mg compared with lansoprazole 30 mg in the treatment of erosive esophagitis. Am J Gastroenterol. 2002; 97(3): 575-83.
11. Fennerty MB, Johanson JF, Hwang C et al. Efficacy of esomeprazole 40 mg vs. lansoprazole 30 mg for healing moderate to severe erosive oesophagitis. Aliment Pharmacol Ther. 2005; 21(4): 455-63. http://doi.org/10.1111/j.1365-2036.2005.02339.x.
12. Labenz J, Armstrong D, Lauritsen K et al. A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: the EXPO study. Aliment Pharmacol Ther. 2005; 21(6): 739-46. http://doi.org/10.1111/j.1365-2036.2005.02368.x.
13. Gralnek IM, Dulai GS, Fennerty MB et al. Esomeprazole versus other proton pump inhibitors in erosive esophagitis: a meta-analysis of randomized clinical trials. Clin Gastroenterol Hepatol. 2006; 4(12): 1452-8. http://doi.org/10.1016/j.cgh.2006.09.013.
14. Yang S, Deng W, Xie Z et al. Efficacy and safety of proton pump inhibitors versus vonoprazan in treatment of erosive esophagitis: A PRISMA-compliant systematic review and network meta-analysis. Medicine (Baltimore). 2022; 101(47): e31807. http://doi.org/10.1097/MD.0000000000031807.
15. DeVault KR, Johanson JF, Johnson DA et al. Maintenance of healed erosive esophagitis: a randomized six-month comparison of esomeprazole twenty milligrams with lansoprazole fifteen milligrams. Clin Gastroenterol Hepatol. 2006; 4(7): 852-9.
16. Katz PO, Castell DO, Levine D. Esomeprazole resolves chronic heartburn in patients without erosive oesophagitis. Aliment Pharmacol Ther. 2003; 18: 875-82. http://doi.org/10.1046/j.1365-2036.2003.01771.x.
17. Armstrong D, Talley NJ, Lauritsen K et al. The role of acid suppression in patients with endoscopy-negative reflux disease: the effect of treatment with esomeprazole or omeprazole. Aliment Pharmacol Ther. 2004; 20(4): 413-21. http://doi.org/10.1111/j.1365-2036.2004.02085.x.
18. Mönnikes H, Pfaffenberger B, Gatz G et al. Novel measurement of rapid treatment success with ReQuest: first and sustained symptom relief as outcome parameters in patients with endoscopy-negative GERD receiving 20 mg pantoprazole or 20 mg esomeprazole. Digestion. 2005; 71(3): 152-8. http://doi.org/10.1159/000086784.
19. Johnson DA, Le Moigne A, Hugo V et al. Rapid resolution of sleep disturbances related to frequent reflux: effect of esomeprazole 20 mg in two randomized, double-blind, controlled trials. Curr Med Res Opin. 2015; 31(2): 243-50. http://doi.org/10.1185/03007995.2014.991818.